180 related articles for article (PubMed ID: 30547267)
1. Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients.
Tawada M; Hamada C; Suzuki Y; Sakata F; Sun T; Kinashi H; Katsuno T; Takei Y; Maruyama S; Honda K; Mizuno M; Ito Y
Clin Exp Nephrol; 2019 May; 23(5):689-699. PubMed ID: 30547267
[TBL] [Abstract][Full Text] [Related]
2. Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis.
Sugiyama N; Tawada M; Sun T; Suzuki Y; Kinashi H; Yamaguchi M; Katsuno T; Aten J; Vlahu CA; van Kuppevelt TH; Takei Y; Ishimoto T; Maruyama S; Mizuno M; Ito Y
Clin Exp Nephrol; 2021 Sep; 25(9):1035-1046. PubMed ID: 33999275
[TBL] [Abstract][Full Text] [Related]
3. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.
Ayuzawa N; Ishibashi Y; Takazawa Y; Kume H; Fujita T
Perit Dial Int; 2012; 32(2):159-67. PubMed ID: 21804136
[TBL] [Abstract][Full Text] [Related]
5. Do low GDP neutral pH solutions prevent or retard peritoneal membrane alterations in long-term peritoneal dialysis?
Parikova A; Michalickova K; van Diepen AT; Voska L; Viklicky O; Krediet RT
Perit Dial Int; 2022 May; 42(3):236-245. PubMed ID: 34259088
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
7. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
8. Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on morphology of peritoneal membrane in rats.
Ikehara O; Nishimura H; Naito T; Higuchi C; Sanaka T
Nephron Exp Nephrol; 2005; 100(1):e30-9. PubMed ID: 15731567
[TBL] [Abstract][Full Text] [Related]
9. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation.
Park MS; Kim JK; Holmes C; Weiss MF
Perit Dial Int; 2000; 20 Suppl 5():S33-8. PubMed ID: 11229610
[TBL] [Abstract][Full Text] [Related]
10. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
11. Associations of neutral pH, low-GDP peritoneal dialysis solutions with patient survival, transfer to haemodialysis and peritonitis.
Chen JHC; Johnson DW; Cho Y; Cheetham M; Sud K; Hayat A; Stallard B; Clayton P; Davies CE; Borlace M; Boudville N
Nephrol Dial Transplant; 2024 Jan; 39(2):222-232. PubMed ID: 37429598
[TBL] [Abstract][Full Text] [Related]
12. Increased peritoneal permeability at peritoneal dialysis initiation is a potential cardiovascular risk in patients using biocompatible peritoneal dialysis solution.
Hamasaki Y; Doi K; Tanaka M; Kume H; Ishibashi Y; Enomoto Y; Fujita T; Homma Y; Nangaku M; Noiri E
BMC Nephrol; 2014 Nov; 15():173. PubMed ID: 25361694
[TBL] [Abstract][Full Text] [Related]
13. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.
Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D;
Nephrol Dial Transplant; 2012 Dec; 27(12):4445-53. PubMed ID: 22859794
[TBL] [Abstract][Full Text] [Related]
14. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
15. Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.
De Los Ríos T; Pérez-Martínez J; Portoles J; Lichodziejewska-Niemierko M; Rivera M; Nowicki M; Książek A; Tato AM; Bohnhorst C; Feriani M
Perit Dial Int; 2016 9-10; 36(5):569-72. PubMed ID: 27659931
[TBL] [Abstract][Full Text] [Related]
16. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
17. Vasculopathy plays an important role during the development and relapse of encapsulating peritoneal sclerosis with conventional peritoneal dialysis solutions.
Tawada M; Ito Y; Banshodani M; Yamashita M; Shintaku S; Sun T; Suzuki Y; Kinashi H; Kubo Y; Ando M; Yamaguchi M; Katsuno T; Mizuno M; Kawanishi H
Nephrol Dial Transplant; 2021 Jul; 36(8):1519-1526. PubMed ID: 32437531
[TBL] [Abstract][Full Text] [Related]
18. A new neutral-pH low-GDP peritoneal dialysis fluid.
Himmele R; Jensen L; Fenn D; Ho CH; Sawin DA; Diaz-Buxo JA
Perit Dial Int; 2012; 32(4):444-52. PubMed ID: 22383632
[TBL] [Abstract][Full Text] [Related]
19. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
